Published in Vaccine Weekly, April 29th, 1996
According to a report by writer K.S. Jayaraman in the journal Nature Medicine (1996;2(3):262), the vaccine was developed 15 years ago by researchers at the National Institute of Immunology (NII) in New Delhi.
It is comprised of killed Mycobacterium-W, a fast-growing mycobacterium that shares epitopes with Mycobacterium leprae, the etiologic agent of human leprosy.
Current leprosy treatment, as recommended by the World Health Organization, is a combination of dapsone, rifampicin, and clofazimine. This treatment typically takes two to five...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly